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2Abstract17
The relative abundance of different groups of sulphate reducing bacteria (SRB) in faecal DNA18
collected before and after therapy from patients suffering with Crohn’s disease (CD), irritable bowel19
syndrome (IBS) or ulcerative colitis (UC) has been compared with that from healthy controls. Growth20
tests revealed that SRB were not more abundant in samples from CD patients before treatment than in21
the healthy control group. For most of the 128 samples available, these preliminary results were22
confirmed using degenerate PCR primers that amplify the dsrAB gene. However, some samples from23
CD patients before treatment contained a growth inhibitor that was absent from IBS or UC samples.24
In-depth sequencing of PCR-generated dsrB fragments revealed that the diversity detected was25
surprisingly low, with only 8 strains of SRB and the sulphite reducing bacterium, Bilophila26
wadsworthia, detected above the 0.1% threshold. The proportion of the two major species detected, B.27
wadsworthia and Desulfovibrio piger, was as high as 93.5% of the total SRB population in the healthy28
control group, and lower in all patient groups. Four previously undescribed species were found: it is29
impossible to predict whether they are sulphate or sulphite reducing bacteria.30
31
3Introduction32
A common feature of inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative33
colitis (UC) is the excessive immune response to bacteria that inhabit the intestinal lumen. Despite34
recent progress in defining factors that exacerbate or ameliorate these diseases, their precise causes35
remain poorly defined. Both can be treated with different degrees of success by immunosuppressive36
drugs such as corticosteroids, azathioprine or infliximab. Although enteral feeding to control dietary37
intake is effective in the treatment of Crohn’s disease, this is not so in ulcerative colitis ( King et al.,38
1997). Successful treatment of Crohn’s disease is accompanied by substantial changes in the39
composition of gut microbiota and related immunoglobulins (van den Waaij et al., 2004) but no single40
group of bacteria has been implicated as the unequivocal source of these diseases. Irritable bowel41
syndrome (IBS) is a condition arising from a variety of causes whose symptoms are often similar to42
those of IBD. No intestinal inflammation is present, but as many as 50% of cases have food43
intolerances so that symptoms may be controlled successfully by diet (Wiesner et al., 2009). These44
intolerances have been shown to be related to abnormal fermentation by the colonic microflora (King et45
al., 1998, Dear et al., 2005).46
Two of the major groups of bacteria that dominate the human gut are those that ferment47
complex carbohydrates, lipids or protein to lactate; and those that convert lactate to propionate or48
butyrate. The production of butyrate is significant because it is the preferred energy source for49
colonocytes (Macpherson et al., 1996; Aminov et al., 2006; Louis & Flint, 2009; Mai & Draganov,50
2009) and is both anti-inflammatory and anti-carcinogenic (Hamer et al., 2008; Tazoe et al., 2008). It51
is converted by gastroentestinal bacteria to other compounds that are also anti-inflammatory (Sokol et52
al., 2008). Butyrate is generated from lactate by fermentative bacteria dominated by the Firmicute53
phylum, and a marked deficiency of one species, Faecalibacterium prausnitzii, has been suggested as54
4being correlated with Crohn’s disease. However, this report is unconfirmed because successful55
treatment with enteral diet resulted in a decrease, not an increase, in F. prausnitzii in this patient group56
(Jia et al., 2010). There was no significant deficiency in F. prausnitzii either before or after treatment57
of ulcerative colitis or irritable bowel syndrome patients.58
It has been proposed that the production of an unidentified toxin by intestinal bacteria might59
play a significant role in provoking intestinal inflammation. Anecdotally, in an acute phase, Crohn’s60
disease patients suffer from bad breath typical of hydrogen sulphide production, and the presence of61
high levels of sulphide in their faecal samples has been documented (Pitcher & Cummings, 1996).62
Some sulphate reducing bacteria (SRB) generate sulphide from sulphate using lactate as their preferred63
electron donor, and hence they compete with Firmicutes for their primary source of carbon and energy64
(Roediger et al., 1997; Chapman et al., 1994; Attene-Ramos et al., 2007). It has therefore been65
proposed that sulphate reducing bacteria exacerbate gastrointestinal disease not only by generating a66
toxic product, hydrogen sulphide, but also by depleting the production of beneficial butyrate (Marquet67
et al., 2009: but see also Shatalin et al., 2011). If so, sulphate reducing bacteria might be less abundant68
in patients after successful treatment. Mills et al. (2008) reported that after continuous flow culture69
models of the human colonic microbiota were inoculated with faeces from UC and non-UC volunteers,70
changes in bacterial populations were observed, with elevated numbers of sulphate reducing bacteria in71
the microbiota from UC patients. Furthermore, it is possible that one or more species of sulphate72
reducing bacteria might be associated with gastrointestinal disease. A previous study has revealed that73
the prevalence of Desulfovibrio piger was significantly higher in inflammatory bowel disease patients74
as compared to healthy individuals (Loubinoux et al. 2002). However, results from the literature do not75
show a clear association between sulphate reducing bacteria and IBD (Zinkevich and Beech, 2000;76
5Pitcher et al., 2000; Duffy et al., 2002; Ohge et al., 2005; Manichanh et al., 2006; Collado et al., 2007).77
This might reflect highly diverse microbiota within individual groups and differences in methodology.78
To investigate the possible association between gut disease and SRB, we compared the relative79
abundance of sulphate reducing bacteria in faecal DNA collected before and after therapy from patients80
suffering with Crohn’s disease, irritable bowel syndrome or ulcerative colitis; healthy subjects were81
also recruited as controls. In addition to conventional methods used in previous studies, such as82
recovering growth of SRB, PCR and denaturing gradient gel electrophoresis (DGGE), the diversity of83
SRB in human faeces was also studied by next-generation sequencing (454 sequencing, Roche), which84
allows the identification of SRB species at a DNA level.85
Materials and methods86
Patient recruitment and treatment87
Faecal samples were collected from 21 IBS patients, 20 CD patients and 14 UC patients, as described88
previously (Jia et al., 2010). As controls, 18 healthy subjects were also recruited. Briefly, all volunteers89
were recruited at Addenbrookes Hospital, Cambridge, which functions as a tertiary referral centre for90
IBD. Ethical permission to collect these samples was obtained from Leeds West Ethics Research91
Committee (Ref. 07/Q1205/39) and informed, written consent was obtained from each subject. The92
diagnosis of CD and UC was based on standard endoscopic, radiological and histological findings; all93
subjects with IBS fulfilled the Rome II criteria. The severity of CD symptoms was reflected by the94
Harvey and Bradshaw (1980) Index and an objective measure of inflammation was provided by the95
serum concentration of C-Reactive Protein (CRP), which was determined by the Clinical Biochemistry96
Department, Addenbrookes Hospital. The patients gave a faecal sample at the start of treatment and in97
6most cases again after treatment. Within 48 hours of collection, samples (at 4oC) were sent by courier98
to the University of Birmingham for DNA extraction and preparation of faecal suspension.99
CD patients were treated as described previously (Jia et al., 2010). Apart from water ad libitum,100
their nutritional intake was limited to the elemental diet E 028 Extra (Nutricia, Liverpool UK) in101
quantities calculated individually by a registered dietician according to the Schofield (1985) equation102
until symptoms resolved, which took two to three weeks. Further faecal samples were collected when103
they reached remission. Eleven of the UC patients had received either immuno-modulation or 5-104
aminosalicylic acid therapy prior to this study, and this was continued or introduced for all of the UC105
group, albeit with changes in the drugs prescribed, and increases in the doses used. IBS patients106
received conventional treatment with either low-fibre diet or non-fermentable bulking agents such as107
sterculia. (Weisner et al., 2009). Again, further faecal samples were obtained when the patients108
reached remission.109
DNA extraction and templates preparation for 454 sequencing110
DNA was extracted from each faecal sample and stored as reported previously (Jia et al. 2010). To111
amplify a DNA fragment that is definitive for SRB in environmental DNA, a semi-nested PCR strategy112
(the first round to amplify dsrAB followed by a second round to amplify dsrB) has proven to be much113
more effective for detecting the widest range of species than using only one round of PCR and was114
therefore employed by this study (Miletto et al. 2007). First, 5 forward and 6 reverse degenerate115
primers were used to amplify an approximately 1.9 kb dsrAB fragment from as many SRB as possible116
(Supplementary Table 1). In a total volume of 20 µl, 10 ng of DNA was used as a template with117
HotStarTaq Plus Master Mix Kit (Qiagen) plus 4 µl of Q-solution (Qiagen) according to the118
manufacturer’s instructions. The reaction conditions were: initial denaturation (5 min at 95oC); then 12119
7cycles of denaturation (40 s at 94oC), annealing at temperatures ranging from 60 to 48oC (decreasing120
1oC per cycle, 40 s) and elongation (2 min at 72oC); followed by 23 cycles of denaturation (40 s at121
94oC), annealing (40 s at 48oC) and elongation (2 min at 72oC); and a final extension (10 min at 72oC).122
The PCR product was then used as a template for a second round of PCR to amplify an approximately123
430 bp dsrB fragment including a barcode (also called multiple identifiers, MID) that could represent a124
patient group and be recognised in the following analysis. The design of primers used for the second125
round of PCR was based on previous publications (Geets et al., 2006; Miletto et al. 2007) and was126
made more degenerate to rescue as many SRB species as possible (Supplementary Table 1). The127
reaction conditions were: initial denaturation (5 min at 95oC); then 30 cycles of denaturation (40 s at128
94oC), annealing (40 s at 55oC) and elongation (1 min at 72oC); and a final extension (10 min at 72oC).129
Qualitative estimation of SRB abundance in faeces130
By using a homogeniser, a 0.4 g faecal specimen from each subject was suspended in 3.6 ml of peptone131
water. The suspension was centrifuged at 100 x g for 40 s to remove any remaining solid matter and the132
supernatant was collected and centrifuged at 12,000 x g for 5 min. The pellet obtained was then washed133
twice in 1 ml of TE buffer (10 mM Tris-Cl pH 7.5 containing 1 mM EDTA). The final pellet was134
resuspended in 4 ml of TE buffer supplemented with 100 µl of 40% glycerol, and the suspension was135
aliquoted and stored at – 80oC. To recover the growth of SRB that are able to use lactate as their136
electron donor and sole source of carbon, 0.5 ml of faecal suspension was inoculated into a 9.5-ml137
sulphate-rich growth medium, Postgate B (Postgate, 1984). The cultures were grown anaerobically in138
sealed 10 ml serum bottles. After incubation at 30oC for 21 days, they were photographed and the139
digital pictures were analysed to measure the degree of blackening of the culture. The abundance of140
SRB was gauged according to the amount of black precipitate, ferrous sulphide, formed by SRB. The141
8pure black colour was defined as 99, whereas pure white was defined as 0. The black intensity of each142
culture was determined accordingly, ranging from 4 to 73.143
Because the capacity of Postgate B medium to recover all SRB is not known, the abundance of144
SRB in faeces was also estimated by PCR. The production of a dsrB fragment following two rounds of145
PCR was gauged. In the first round, 10 ng of faecal DNA was used as a template; and in the second146
round, 0.5 µl of the first round PCR product was included in all photographs and used for147
normalization. The final PCR product (10 µl) was loaded on a 0.8 % agarose gel to check for a specific148
band with a length of approximately 430 bp. The samples were divided into five groups based on the149
production of dsrB: score 1, no specific band could be detected; score 2, a weak band was detected150
when the undiluted first round PCR product was used as a template; score 3, a strong band was151
detected when the undiluted first round PCR product was used as a template; score 4, a strong band152
was detected when a 10-fold dilution of first round PCR product was used as a template; and score 5, a153
strong band was detected when a 1000-fold dilution of first round PCR product was used as a template.154
Denaturing Gradient Gel Electrophoresis155
The same nested PCR strategy was used to prepare template DNA for DGGE. The product from the156
first round of PCR, dsrAB, was used as a template to amplify dsrB but with a 40-bp GC clamp (Miletto157
et al. 2007). The design of primers used for second round of PCR was based on previous publications158
(Geets et al., 2006; Miletto et al. 2007) and was made more degenerate to rescue as many SRB species159
as possible (Supplementary Table 1). An alignment of dsrB sequences has revealed that the improved160
primers should be effective for over 95 % of all known SRB (allowing 2 mismatches). The reaction161
conditions were: initial denaturation (5 min at 95oC); then 30 cycles of denaturation (40 s at 94oC),162
9annealing (40 s at 55oC) and elongation (1 min at 72oC); and a final extension (10 min at 72oC). The163
dsrB-GC PCR product was purified by using QIAquick Gel Extraction Kit (Qiagen, Germany).164
In order to reveal the diversity of SRB, the dsrB-GC fragments (with the GC clamp) derived165
from different species in each patient were separated by DGGE using the DCode Universal Mutation166
Detection System (Bio-Rad, USA). A gradient of 40 to 70% denaturant was constructed in a 1 mm167
thick 8% (w/v) polyacrylamide gel by mixing a high density solution (70%) with a low density solution168
(40%) using the Gradient Delivery System. The 100% (w/v) denaturant solution contains 7 M urea and169
40% (v/v) formamide. To visually check the formation of the gradient, 300 µl of DCode dye solution170
was added into 15 ml of high density solution. The purified PCR product was mixed with 6 x171
bromophenol blue loading buffer and loaded into the parallel gradient gel. Prior to loading, the gel had172
been pre-heated to 60oC in 7 litres of 0.5 x TAE buffer. The gel was initially run at 150 V for 5 min173
without circulating the TAE buffer in the tank to facilitate the access of PCR products into the gel, and174
then at 75 V for 21 h at 60oC with the buffer circulating continuously. Following electrophoresis, the175
gel was stained for 30 min in 250 ml of 0.5 x TAE buffer containing 1 µg.ml-1 ethidium bromide. The176
gel was photographed in a UV transilluminator and each dsrB-GC band representing a different SRB177
resource was removed and soaked in 130 µl of nuclease-free water. After eluting DNA into water178
overnight, a solution containing 50 ng of DNA was evaporated down to 7 µl and sequenced by using179
primer DSR4R. The sequencing data were analysed using NCBI blast.180
Identification of SRB in human faeces by 454 sequencing181
Four groups of subjects were recruited in this study to produce seven groups of samples: patients with182
IBS before and after treatment; patients with CD before and after treatment; patients with UC before183
and after treatment; and one healthy control group. Unlike the control group, in which a dsrB fragment184
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was amplified successfully from every sample, some patients did not carry any SRB that could be185
amplified and therefore 454 sequencing could not be undertaken. As a result, only 9 subjects in each186
group were selected and equimolar amounts of template from each patient were pooled. When a before-187
treatment group was compared with the corresponding after-treatment group, the sequencing data were188
not for completely paired patients. For the before- and after-treatment UC groups, 7 out of 9 patients189
were paired; for the 2 CD groups, 5 out of 9 patients were paired; and for the 2 IBS groups, 3 out 9190
patients were paired. The 7 patient pools were sequenced by the Functional Genomics and Proteomics191
Laboratory at the University of Birmingham, and 200,133 sequences were extracted.192
The sequencing data were analysed by using software Geneious® (Biomatters Ltd, New193
Zealand). The sequences with low quality (shorter than 150 bp or longer than 440 bp, 15.3% of total)194
were removed before further analysis. For each pool, 24,220 high-quality sequences were produced on195
average (169,539 sequences in total). In order to handle the data efficiently, the data produced for one196
pool were further divided into batches, each comprising approximately 2,500 sequences. They were197
then aligned by using software MUSCLE, and a neighbour joining phylogenetic tree was constructed198
based on the alignment result. The distance between clusters in a tree reflects the diversity of SRB199
found within a patient pool. Sequences within one cluster (diverging distance less than 0.03) were200
extracted and a consensus sequence was produced. Consistent with the report of Kjeldsen et al. (2007),201
clusters whose consensus amino acid sequences were over 97% identical were considered as one202
phylotype. Duplicate samples of high quality sequences were analysed from 7 of the pools to check that203
sufficient data had been analysed to generate a reproducible result. In total, 55,708 out of 169,539204
sequences were analysed as 21 datasets, which generated 21 phylogenetic trees (Supplementary figures205
1 – 21). A further comparison between the trees revealed that there were 16 phylotypes, i.e. 16206
sulphate- or sulphite-reducing bacterial species. In addition, 10 to 20% of the sequences within each207
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bacterial group were analysed using NCBI blast, and the identification reports validated the grouping208
method based on alignment. The DNA consensus sequences were also translated into amino acid209
sequences, which again confirmed the grouping method. Furthermore, each patient group could be210
considered as two sub-groups, because four samples from one group were pooled and labelled with a211
unique barcode whereas the other five were labelled with a different barcode. Comparison of the two212
subgroups revealed whether the diversity of SRB was consistent. By combining data for the two213
subgroups, it was possible to determine whether one patient group as a whole was different from other214
groups.215
In addition to the study based on pooled samples, 6 before-treated CD patients were analysed216
individually by 454 sequencing. To investigate whether the composition of SRB populations had217
changed in response to the ED therapy, the treated samples from 4 out of the 6 patients were also218
sequenced. Samples from the three control subjects were also sequenced to test whether the219
composition of SRB was similar between healthy controls.220
Statistical analysis of the data221
Results were assessed by non-parametric methods: Mann-Whitney U (MWU) test to compare the222
healthy control group with patient groups; and Spearman r for correlation analysis. These analyses223
were carried out using the Instat statistical package (GraphPad).224
Results225
The abundance of SRB in faecal suspensions from different patient groups226
In this study, 128 faecal samples were donated by 7 groups of patients: CD, UC and IBS patients both227
before and after treatment, and one healthy control group. For the 128 samples, the abundance of SRB228
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was estimated by assessing the amounts of ferrous sulphide produced by SRB after aliquots of faecal229
suspensions had been grown anaerobically in Postgate medium B. Depending on the abundance of230
SRB in each inoculum, a black precipitate of iron sulphide had accumulated after 1 to 14 days. After 21231
days at 30C, the intensity of the black precipitate in each culture was measured by densitometry232
(Table 1). The resulting data for each patient group were analysed using the Mann-Whitney test to233
detect differences between groups. This analysis revealed that there was significantly less growth of234
SRB in samples from CD patients before treatment than in the healthy control group (Mann Whitney235
test, p=0.017). There had been little change in SRB abundance following enteral diet treatment, but236
almost certainly due to the small number of samples available for analysis, the P value for the237
difference compared with the healthy control group had increased to 0.065. Samples from UC patients238
before treatment also appeared to give less SRB growth compared with the healthy control group, but239
due to the small number of samples available, this apparent difference was not statistically significant.240
In contrast, there were no significant differences between the healthy controls and the IBS patients241
either before or after treatment.242
The abundance of SRB DNA in faecal DNA determined by PCR analysis243
Dissimilatory sulphite reductase encoded by dsrAB is an essential and highly conserved enzyme in244
sulphate reducing bacteria. The occurrence of similar sequences is limited to organisms that reduce245
other sulphur compounds such as organosulphates or sulphite and to sulphur oxidizing that are unlikely246
to be abundant in human faeces. Degenerate primer sets have been developed that amplify a 1.9 kb247
fragment of the dsr operon from virtually all known SRB (Zverlov et al., 2005). These primers were248
used to amplify PCR products using faecal DNA as template. The abundance of SRB in each sample249
was estimated on the basis of the quantity of DNA template required to amplify a PCR product that was250
visible by gel electrophoresis (Table 1). This independent qualitative method for estimating the251
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abundance of SRB also revealed significantly less SRB DNA in faecal samples from CD patients and252
in the healthy control group. Statistical analysis again revealed that this difference compared with the253
healthy control group was statistically significant before treatment (Mann Whitney test p=0.0136): the254
p value for the comparison of the post-treatment samples with the control group was 0.066. As for the255
growth-dependent assays, there were no significant differences in the abundance of dsrB DNA in256
samples from UC and IBS patients and the healthy control group either before or after treatment.257
Comparison of data for individual samples obtained by growth experiments and PCR analysis258
There was a significant correlation between the estimated relative abundance of SRB obtained for each259
individual sample by using the two independent methods (Supplementary Fig. S22: Spearman r=260
0.3994, p< 0.01, number of XY pairs = 125; culture data were not available for 3 patients). It was261
therefore concluded that, to a first approximation, both methods provide valid qualitative estimates of262
the relative abundance of SRB in faecal samples, and therefore that the PCR approach could be263
extended to compare the diversity of SRB within and between samples.264
Inhibition of SRB growth by faecal suspensions from some CD patients265
Despite the significant correlation between results of growth tests and PCR analysis of faecal DNA,266
clear discrepancies were apparent in the results from the two methods for some of the CD samples. For267
each of the 18 healthy controls, both growth tests and PCR amplification data indicated a high268
abundance of SRB, and the ratios of the two scores ranged between 11 and 18 (on average 15). In269
contrast, in 8 out of the 22 samples from CD patients before treatment, PCR analysis revealed a high270
level of SRB DNA, but relatively low SRB growth occurred when suspensions were used to inoculate271
Postgate medium B. The ratios of the two scores for these 8 samples were all below 11, including a272
ratio of 2 for sample 82 and less than 1 for sample 148. This lack of growth despite the presence of273
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SRB DNA might indicate either that the SRB in these samples were no longer viable, or that the major274
SRB species present grew poorly in Postgate medium B. A further possibility was that the faeces275
contained an inhibitor of SRB growth. To investigate whether samples 82 and 148 from CD patients276
before treatment contain an inhibitor of SRB growth, 0.5 ml of faecal suspension from these two277
samples was incubated in Postgate medium B with samples 116 or 126 in which SRB growth was rapid278
and abundant. Both samples strongly inhibited the growth of the positive controls (Fig. 1a and 1b).279
Dilution of these samples resulted in progressively less growth inhibition of the positive controls,280
confirming that inhibition was concentration-dependent. Growth inhibition was also lost on subsequent281
subculturing, presumably also due to dilution of the growth inhibitor in the original faecal sample (Fig.282
1c). Sample #82 was from patient CG before treatment: the post-treatment sample #88 from this283
patient was also incubated with SRB-positive controls: it did not inhibit SRB growth (Fig. 1b). Further284
investigation established that 6 out of the 8 samples that gave poor SRB growth contained inhibitory285
factors for the growth of SRB, and in all six cases, growth inhibition was lost or had decreased286
substantially in samples from the same patient post-treatment. Samples from IBS and UC patients in287
which SRB DNA was abundant but growth in Postgate medium B was poor were also tested for the288
presence of growth-inhibitory factors. None of these samples inhibited growth of the positive controls.289
DGGE investigation and sample selection for 454 sequencing290
In initial experiments, the 1.9 kb dsrAB fragments were used as templates to generate 390 bp PCR291
products with clamps suitable for analysis by DGGE. To provide standards to calibrate DGGE gels,292
PCR products were also generated from DNA isolated from pure cultures of well-characterised293
sulphate reducing bacteria, and also from B. wadsworthia. Multiple bands following electrophoresis294
revealed the presence of PCR products of different GC content, suggesting the presence of a range of295
different SRB in these samples (Supplementary figure S23). However, multiple bands were also296
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obtained from PCR products generated using the same set of degenerate primers and chromosomal297
DNA purified from pure cultures of known SRB. Bands extracted from some of these gels were298
sequenced, and their origins were confirmed. By using NCBI blast, three species, B. wadsworthia, D.299
vulgaris Hildenborough and Desulfovibrio sp. NY682 were found in the samples tested. However,300
extensive experiments with this technique gave data too variable for reliable use in detecting minority301
populations or in determining the relative abundance of different SRB groups. The method was also too302
insensitive to detect minority populations that might be relevant to disease. The DGGE analysis was303
therefore abandoned in favour of in-depth DNA sequencing of PCR products.304
Diversity of sulphate reducing bacteria in human faecal DNA305
The 1.9 kb dsrAB fragment was readily generated using faecal DNA from all of the 18 samples from306
the control group, and all of these faecal samples gave abundant growth of SRB in Postgate medium B.307
Nine of these samples were used as templates to generate two pools (one pool from five samples and308
the other from four samples) of 430 bp bar-coded PCR products suitable for in-depth DNA sequencing.309
A further 12 pools of 430 bp bar-coded PCR products were also generated from faecal DNA from CD,310
UC and IBS patients before and after treatment (Table 2). As a result, the 454 sequencing data would311
reflect the most abundant SRB species present in the samples. However, the profile for CD and UC312
patients would not be quite complete because it was impossible to include samples from which dsrB313
fragments could not be amplified.314
Equal quantities of DNA from each of the 14 resulting pools were mixed and sequenced. The315
14 pools yielded 169,539 DNA sequences of good quality, of which over 99% could unequivocally be316
assigned to a dsrB fragment from an SRB in an identified pool of PCR products. The numbers of317
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sequences obtained from individual pools ranged from 1,591 in one of the pools of samples from IBS318
patients after treatment to 24,100 sequences from a pool of UC patients after treatment.319
As a first step in data analysis, the diversity and relative numbers of SRB amongst over 2,500320
randomly selected sequences were then analysed and compared with a further 2,500 sequences from321
the same sample. The results of these duplicate analyses were essentially identical (Supplementary Fig.322
S24), suggesting that it was sufficient to analyse 2,500 sequences from each pool to detect species323
present at more than 0.1% of the total SRB population.324
The diversity of SRB in each pool was then determined, as described in detail in the Methods325
section. As shown in Table 2, each of the 7 patient groups could be considered as two sub-groups. The326
two sub-groups were compared to determine whether the diversity of SRB was consistent within one327
patient group; and, when the results of the two sub-groups were combined, whether one patient group328
as a whole was different from others (Fig. 2 - comparison between 7 patient groups; Table 3-329
comparison between 2 subgroups within one patient group).330
The diversity and relative distribution represented in the 14 pooled samples were then331
determined by analysis of 55,708 sequences out of the 169,539 good-quality sequences available332
following 454 sequencing. There were two key observations from this initial series of experiments.333
First, the diversity detected was surprisingly low, with only 8 groups of dsrB sequences other334
than the sulphite reducing bacterium, B. wadsworthia, detected above the 0.1% threshold (Fig. 3). Four335
of the SRB are either identical or closely related to known species: D. piger; D. vulgaris336
Hildenborough; D. sp. NY682; and D. desulfuricans F28-1. Note that the remaining four species might337
not be SRB, but bacteria able to reduce sulphite or organic oxidized sulphur compounds.338
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Secondly, four previously undescribed species designated strains A, B, C and D were found:339
strains A and B were more widely distributed than strains C and D. Because these results were from340
pools of DNA samples from 4 or 5 individuals, these strains might have been carried by only one or341
two people. Database searches revealed that on the basis of the dsrB sequences, the closest relative to342
species A is D. desulfuricans F28-1 (93% sequence identity); dsrB from species B is 84% identical to343
that from D. oxamicus; dsrB from C is 80% identical to Desulfotomaculum sp. Lac2; and D is 88%344
identical to D. simplex. It is impossible to predict whether the 4 new bacterial groups have sulphate or345
sulphite reducing capacity as they are so different from any known bacteria (Fig. 3; Table S2).346
Relative abundance of SRB in faeces347
The data described above enabled the relative abundance of the various strains to be calculated. D.348
piger was the most abundant SRB present in 9 of the 14 pools. However, its abundance varied widely349
from pool to pool and no consistent trends were apparent. For example, D. piger was not detected in350
one of the samples, pool 11, from IBS patients before treatment but constituted 44.7% of the dsrB351
sequences in the other pool of patients (pool 4; Table 3). There was similar variation in the abundance352
of D. piger in pools from IBS patients post-treatment, with none detected in pool 12, but 36% in pool 5.353
B. wadsworthia was more abundant than all of the SRB in 9 of the 14 pooled samples, but again its354
relative abundance varied widely between pools (Table 3).355
Distribution of SRB in individuals356
The most significant differences in SRB populations revealed by PCR analysis were between CD357
patients before treatment and the healthy controls. In order to identify any differences in SRB358
populations before and after treatment, 13 individual samples were investigated, including 3 healthy359
controls, 4 pairs of CD patients both before and after treatment, and 2 other CD patients before360
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treatment (Table 4). In the 3 healthy individuals, the proportion of the 2 major species contributed over361
90% of all dsrB sequences, similar to the pooled data. However, the ratios of B. wadsworthia to D.362
piger varied over a wide range. Among the 6 CD patients before treatment, 4 patients carried a much363
lower proportion of B. wadsworthia (below 27.8%) compared to the average level in the healthy364
control group (67.7%). Subsequent analysis of the 2 exceptional CD patients (Sample #47 and #128)365
with high levels of B. wadsworthia revealed that the severity of disease in patient 128 was very low (2366
mg/ml CRP), while in patient #47, no other sulphate or sulphite reducing bacterium was detected apart367
from B. wadsworthia. This result is consistent with the results from the pooled data: a low proportion368
of B. wadsworthia is likely to correlate with CD. However, based on the observation of these four369
patients, effective treatment determined either by the Harvey and Bradshaw Index or by the370
concentration of C-Reactive Protein (Table 5) does not always lead to an increase in the proportion of371
B. wadsworthia. Clearly many more data from individuals before and after treatment will be required372
for any statistically significant conclusions to be drawn. Based only on the 13 tested individuals, there373
was no obvious association between the presence of species A and an abnormal gut environment. No or374
very low levels of species C were found in CD patients, but it was present only in one of the 3 healthy375
individuals investigated. Based only on the 13 tested individual samples, there was no obvious376
association between the presence of species A or C and a healthy gut environment. The relatively high377
proportion (approximately 6%) of species D observed in the CD patient pool was likely contributed by378
one individual (patient sample #140), carrying species D at a level of 60% of all SRB. Again, no379
statistically meaningful conclusion could be drawn from such a small sample.380
Discussion381
To our knowledge, this is the first attempt to define the relative abundance and diversity of SRB in the382
human gut. Our primary objective was to determine by in depth sequencing of individual DNA383
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molecules whether the presence of one or more species, or their relative abundance, could be correlated384
with gut disease. Once they had been screened for variation due to sequencing errors, highly385
significant data were obtained. The results are therefore important in that they demonstrate that for386
bacteria for which the more traditional method of analysing 16S-ribosomal DNA sequences is387
unreliable, a combination of bar-coded primers and DNA sequencing of genes for a highly conserved388
metabolic enzyme can provide a useful alternative approach to analyse complex bacterial communities389
that might be associated with human disease.390
Three major caveats should be considered in interpreting the data obtained from this study.391
First, two rounds of PCR were required to generate the template molecules that were sequenced. In392
any PCR reaction involving degenerate primers and community DNA, some templates will be393
amplified more than others. Secondly, primer design is critical because only those templates394
recognised by the primers can be amplified. For these reasons, it was essential to provide independent395
data to confirm that at least the major groups of SRB present in human faeces can be detected using the396
methods described in this study. The third caveat is that samples that failed to generate sufficient PCR397
product could not be included in the sequencing. Thus it is conceivable, but we believe unlikely, that398
new SRB species might occur only in these samples, and hence would have been overlooked in this399
study. With these caveats in mind, several important conclusions can be drawn from our data.400
Due to the scarcity of SRB in human faeces, the 1.9 kb dsrAB fragments produced from the first401
round of PCR was hardly detected on an agarose gel whereas the second round PCR product, dsrB, was402
visible for most samples. Thus, the amount of SRB in each patient was scored by the amount of first403
round PCR product required to produce a clearly visible dsrB band on an agarose gel. The faecal404
samples were classified into 5 groups according to the PCR scores. To explore the possibility that our405
data were invalidated during the first round of PCR, the abundance of SRB in each individual faecal406
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sample was first assessed for its ability to generate a black precipitate of iron sulphide, which is407
indicative of SRB growth. The data correlated significantly with the PCR scores (Supplementary Fig.408
S22), which suggests that most of the major groups of SRB had been detected. However, there were409
two types of deviation from the general trend. First, 6 out of 8 of the samples from CD patients before410
treatment were shown to contain an inhibitor of SRB growth. The PCR assay was therefore more411
reliable than the growth assay for these samples. Conversely, two out of 28 UC samples (#14 and #32),412
two out of the 41 CD samples (#123 and 124) and 6 out of 42 IBS samples (#17, #64, #86, #90, #72413
and #68) gave abundant formation of iron sulphide, but the PCR primers failed to detect the dsrAB414
genes in these samples. In this context it was surprising that no D. fairfieldensis was detected in any415
of our sample (see, for example, Loubinoux et al., 2002). This bacterium has recently been implicated416
in human disease (Gaillard et al., 2011). Thus despite the generally good correlation between growth417
tests and the PCR assay, further improvements to the primer set are required for the PCR assay to be418
completely reliable. An example of such an improvement was published after this work had been419
completed (Steger et al., 2011).420
The DGGE experiments provided an indication of the likely reliability of the second round of421
PCR using two independent sets of primers, but identical DNA templates. Comparable data for the422
relative abundance of B. wordsworthii and D. piger were obtained from both DNA sequencing and423
analysis of DGGE gels. This correlation extended to the three other previously characterized SRB424
found in individual samples. However, the DGGE method was insufficiently sensitive to be used to425
detect minority SRB populations426
If all sulphate and sulphite reducing bacteria in each faecal DNA sample were defined as 100%,427
then B. wadsworthia and D. piger contributed 86% on average to the overall SRB (Table 3 and Fig 2)428
and were the major species of sulphate or sulphite reducing bacteria detected in this study. The429
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proportion of the two species was as high as 93.5% in the healthy control group, and lower in all430
patient groups. After treatment, the proportion of the two species had increased slightly in all three431
disease groups. In the CD patient group before treatment, the proportion of B. wadsworthia (41.9%)432
was much lower than that in the healthy group (67.7%) or any other patient group; after treatment, the433
proportion of B. wadsworthia had increased to a level similar to the healthy group. Also in this group434
before treatment, the proportion of D. piger (36.7%) was higher than that in the healthy group (25.8%)435
or any other patient group; the corresponding figure decreased to a level similar to the healthy group in436
response to treatment. In all of the 3 patient groups, after treatment, there was always an increase, to437
different extents, in the ratio of B. wadsworthia to D. piger. It is notable that the level of new species A438
is very low in healthy controls (0.48%) compared to patients with any of the 3 diseases (in a range of 6439
to 12%). Following treatment, the proportion of species A decreased in every disease group, especially440
in CD patients (from 8.7% to 1.6%). New species C was found almost only in the healthy group; and441
new species D was found almost only in the CD group. If these preliminary results can be confirmed in442
a much more extensive study, they raise many interesting questions. For example, could a relatively443
low level of B. wadsworthia or high level of D. piger be used as an indicator to distinguish CD from444
the other 2 gut diseases? Does an effective treatment always lead to a decrease in the proportion of D.445
piger or an increase in the proportion of B. wadsworthia? Could the presence of new species A be used446
as an indicator for abnormal gut environment, or the presence of new species C be used as an indicator447
for healthy gut environment? Does the presence of new species D contribute to the aetiology of CD?448
Are species A B, C and D sulphate reducing bacteria, or prokaryotes that reduce organosulphur449
compounds, or sulphite? Does the observation in pooled data reflect the distribution of SRB in each450
individual? Finally, could the presence of a growth inhibitor in CD patients be developed as a useful451
tool in diagnosis?452
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In summary, despite its acknowledged limitations, this study has indicated some clear453
objectives for future research, and methods applicable to answer the many questions raised.454
Acknowledgement455
This work was funded by The Wellcome Trust (Grant No. WT080238MA).456
References457
Aminov RI, Walker AW, Duncan SH, Harmsen HJM, Welling GW & Flint HJ (2006) Molecular458
diversity, cultivation, and improved detection by in situ hybridization of a dominant group of459
human gut bacteria related to Roseburia spp. or Eubacterium rectale. Appl Environ Microbiol 72:460
6371-6376.461
Chapman MAS, Grahn MF, Boyle MA, Hutton M, Rogers J & Williams NS (1994) Butyrate oxidation462
is impaired in colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 35: 73-76.463
Collado MC, Calabuig M & Sanz Y (2007) Difference between the faecal microbiota of coeliac infants464
and healthy controls. Curr Issues Intest Microbiol 8: 9-14.465
Dear KLE, Elia M & Hunter JO (2005) Do interventions which reduce colonic fermentation improve466
symptoms of irritable bowel syndrome? Dig Dis Sci 50: 758-766.467
Duffy M, O’Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP & Kirwan WO (2002)468
Sufate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial469
adenomatous polyposis. Dis Colon Rectum 45: 384-388.470
Gaillard T, Pons S, Darles C, Beausset O, Monchal T & Brisou P (2011) Desulfovibrio fairfieldensis471
bacteremia associated with acute sigmoiditis. Med Mal Infect 41: 267-268.472
23
Geets J, Borrenans B, Diels L, Springael D, Vangronsveld J, van der Lelie D & Vanbroekhoven K473
(2006) DsrB gene-based DGGE for community and diversity surveys of sulphate-reducing bacteria.474
J Microbiol Methods 66: 194-205.475
Hamer HM, Jonkers D Venema K, Vanhoutvin S, Troost FJ & Brummer RJ (2008) Review article: the476
role of butyrate in colonic function. Aliment Pharmacol Ther 27: 104-119.477
Harvey RF & Bradshaw JM (1980) A simple index of Crohn’s disease activity Lancet 1: 54.478
Jia W, Whitehead RN, Griffiths L, Dawson C, Waring RH, Ramsden DB, Hunter JO & Cole JA (2010)479
Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS Microbiol480
Lett 310: 138-144.481
King TS, Woolner JT & Hunter JO (1997) Dietary treatment of Crohn’s disease. Aliment Pharm482
Toxicol 11: 17-31.483
King TS, Elia M & Hunter JO (1998) Abnormal colonic fermentation in irritable bowel syndrome.484
Lancet 352: 1187-1189.485
Kjeldsen KU, Loy A, Jakobsen TF, Thomsen TR, Wagner M & Ingvorsen K (2007) Diversity of486
sulphate-reducing bacteria from an extreme hypersaline sediment. Great Salt Lake (Utah). FEMS487
Microbiol Ecol 60: 287-298.488
Loubinoux J, Bronowscki J-P, Pereira IAC, Mougenel J-L & Faou AEL (2002) Sulphate-reducing489
bacteria in human feces and their association with inflammatory bowel disease. FEMS Microbiol490
Ecol 40: 107-112.491
Louis P & Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria492
from the human large intestine. FEMS Microbiol Lett 294: 1-8.493
24
Louis P, Young P, Holtrop G & Flint HJ (2009) Diversity of human colonic butyrate-producing494
bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol495
In press.496
Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J & Bjarnason I (1996) Mucosal antibodies in497
inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365-375.498
Mai V & Draganov PV (2009) Recent advances and remaining gaps in our knowledge of associations499
between gut microbiota and human health. World J Gastroenterol 15: 81-85.500
Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C,501
Chardon P, Marteau P, Roca J & Dore J (2006) Reduced diversity of faecal microbiota in Crohn’s502
disease revealed by a metagenomic approach. Gut 55: 205-211.503
Marquet P, Duncan S, Chassard C, Bernalier-Donadille A & Flint HJ (2009) Lactate has the potential504
to promote hydrogen sulphide formation in the human colon. FEMS Microbiol Lett 299: 128-134.505
Miletto M, Bodelier PL & Laanbroek HJ (2007) Improved PCR-DGGE for high resolution diversity506
screening of complex sulfate-reducing prokaryotic communities in soils and sediments. J Microbiol507
Methods 70: 103-111.508
Mills DJS, Tuohy KM, Booth J, Buck M., Crabbe MJC, Gibson GR & Ames JM (2008) Dietary509
glycated protein modulates the colonic microbiota towards a more detrimental composition in510
ulcerative colitis patients and non-ulcerative colitis subjects. J Appl Microbiol 105: 706-714.511
Ohge H, Furne JK, Springfield J, Rothenberger DA, Madoff RD & Levitt MD (2005) Association512
between fecal hydrogen sulphide production and pouchitis. Dis Colon Rectum 48: 469-475.513
25
Pitcher MCL & Cummings JH (1996) Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut514
39: 1-4.515
Pitcher MCL, Beatty ER & Cummings JH (2000) The contribution of sulphate reducing bacteria and 5-516
aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46: 64-72.517
Postgate JR (1984) Genus Desulfovibrio Desulfovibrio Kluyver and van Niel 1936. In NL Krieg & JG518
Holt (ed.) Bergey’s manual of systematic bacteriology, vol.1, p. 666-672. The Williamms and519
Wilkins Co., Baltimore, MD.520
Roediger WEW, Moore J & Babidge W (1997) Colonic sulphide in pathogenesis and treatment of521
ulcerative colitis. Dig Dis Sci 42: 1571-1579.522
Schofield WN (1985) Predicting basal metabolic rate, new standards and review of previous work.523
Hum Nutr Clin Nutr 39C: 5-41.524
Shatalin K, Shatalina A, Mironov A & Nudler E (2011) H2S: A universal defense against antibiotics in525
bacteria. Science 335: 986-990.526
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ et al. (2008)527
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut528
microbiota analysis of Crohn’s disease patients. Proc Natl Acad Sci USA 105: 16731-16736.529
Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI & Kuwahara A (2008) Roles of short chain fatty acid530
receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 59 (Suppl. 2): 251-262.531
van der Waaij LA, Kroese FG, Visser A, Nelis GF, Westerveld BD, Jansen PLM & Hunter JO (2004)532
Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur J Gastroenterol533
Hepatol 16: 669-674.534
26
Wiesner M, Naylor SJ, Copping A, Furlong A, Lynch AG, Parkes M & Hunter JO (2009) Symptom535
classification in irritable bowel syndrome as a guide to treatment. Scand J Gastro 44: 796-803.536
Zinkevich V & Beech IB (2000) Screening of sulphate-reducing bacteria in colonoscopy samples from537
healthy and colitic human gut mucosa. FEMS Microbiol Ecol 34: 147-155.538
Zverlov V, Klein M, Lucker S, Friedrich MW, Kellermann J, Stahl DA, Loy A & Wagner M (2005)539
Lateral gene transfer of dissimilatory (bi)sulfite reductase revisited. J Bacteriol 187: 2203-2208.540
541
27
Figure legends.542
Fig. 1. Inhibition of SRB growth by faecal suspensions prepared from samples donated by some CD543
patients. In a sealed serum bottle, 9.5 ml of Postgate medium B was inoculated with 0.5 ml of faecal544
suspension. Photographs were taken after 21 days of growth at 30oC. (a) Cultures inoculated with545
sample #38, #116 and #139 were used as positive controls. The culture inoculated with sample #148546
did not form a black precipitate of FeS possibly due to the presence of inhibitors of SRB growth. When547
the positive controls were mixed with sample #148, growth and FeS formation were severely inhibited.548
(b) A 0.5 ml inoculum from the cultures with sample #148 alone, or #148 plus #38, #116 or #139 were549
subcultured into 9.5 ml of fresh Postgate B medium. After a further 21 days, cultures were550
photographed and compared with the starting cultures. (c) Samples obtained from the same patient551
before treatment (#82) and after treatment (#88) were mixed with a positive control #126, and the552
effect on growth was tested. Growth SRB in the positive control samples was inhibited by 6 out of the553
8 faecal samples from CD patients before treatment that gave a poor correlation between the level of554
growth and abundance of dsrB DNA estimated by PCR.555
Fig. 2. Distribution of 4 types of SRB in 7 patient groups. The histogram shows relative abundance in556
the seven sample groups of dsrB DNA from four species (the sulphite reducing bacterium, Bilophila557
wadsworthia, Desulfovibrio piger and two unknown species) expressed a percentage of the total558
number of SRB sequences obtained.559
Fig. 3. Consensus sequences of the 9 phylotypes found in this study and the 8 reference species. The560
phylotype labels 100% B. wadsworthia, 99% D. piger, 98% D. desulfuricans F28-1 and 98%561
Desulfovibrio NY682 overlap the labels of their reference species, as they are too similar to be562
distinguished on the dendrogram.563
564
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Table 1. Abundance of SRB in human faeces estimated by recovering growth and PCR565
Patient Sample
No.
Before
FeS
formed
PCR
score
Sample
No.
After
FeS
formed
PCR
score
Patient Sample
No.
Before
FeS
formed
PCR
score
Sample
No.
After
FeS
formed
PCR
score
Healthy UC
AA 11 73 5 DA 13 17 2 22 15 3
AB 15 66 5 DB 14 4 4 24 63 4
AC 16 71 5 DC 23 29 3 35 73 3
AD 37 71 5 DD 28 22 2 32 9 4
AE 40 56 5 DE 30 37 4 60 73 5
AF 42 73 4 DF 31 54 5 34 72 5
AG 43 66 5 DG 38 71 5 49 72 5
AH 44 72 5 DH 51 34 4 62 19 2
AI 50 71 4 DI 81 n/a 4 170 n/a 3
AJ 54 n/a 4 DJ 98 58 5 108 62 4
AK 71 68 5 DK 102 72 4 111 58 4
AL 74 71 4 DL 116 72 5 120 72 5
AM 95 64 4 DM 139 72 5 155 69 4
AN 114 65 4 DN 160 60 5 165 71 4
AO 145 70 5
AP 146 58 5
AQ 168 71 5
AR 169 69 5
Mean 68 4.7 46 4.1 56 3.9
STDV 5.0 0.5 24 1.1 24 0.9
IBS CD
BA 8 73 1 9 72 4 CA 18 56 4 27 8 2
BB 12 60 4 29 38 4 CB 39 42 5 66 24 3
BC 17 18 5 25 62 5 CC 46 32 3 56 13 3
BD 20 72 4 45 73 5 CD 47 71 4 73 43 4
BE 36 71 4 90 21 4 CE 53 69 4 61 71 5
BF 48 71 5 69 72 5 CF 57 61 5 65 65 5
BG 52 70 4 72 16 4 CG 82 9 4 88 18 4
BH 55 36 4 159 70 4 CH 93 5 5 127 73 5
BI 58 18 4 76 59 4 CI 117 58 2 123 56 1
BJ 63 42 4 70 50 1 CJ 121 29 3 141 48 4
BK 64 16 5 68 21 5 CK 124 58 1 138 47 3
BL 84 69 5 89 66 5 CL 126 66 5 163 71 5
BM 86 29 5 106 55 5 CM 128 71 5 133 72 5
BN 100 64 5 134 70 5 CN 131 7 3 136 25 1
BO 104 72 4 129 72 5 CO 137 35 1 157 59 4
BP 105 65 5 150 59 1 CP 140 72 4 147 70 5
BQ 110 70 4 115 68 4 CQ 142 70 5 149 70 5
BR 112 71 4 176 69 4 CR 143 68 4 154 72 5
BS 113 66 4 118 68 4 CS 164 71 5 172 69 5
BT 122 35 4 125 70 4 CT 166 13 3 175 19 4
BU 162 72 5 167 71 4 CU1 148 4 5
Mean 55 4.2 58 4.1 48 3.8 50 3.9
STDV 21 0.9 18.5 1.1 25 1.3 23 1.3
566
Note 1. Patient CU did not donate a follow-up sample, thus his/her sample was not used for the calculation of567
mean and standard deviation.568
n/a: not assayed.569
570
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Table 2. Pooled and individual samples used in two 454 sequencing experiments571
Barcode
Pool No.
Patient
No.
Sample
No.
Before
FeS
formed1
PCR
score
Barcode
Pool No.
Patient
No.
Sample
No.
After
FeS
formed1
PCR
score
Pooled samples used for the first 454 sequencing experiment
Healthy
1
AA 11 73 5
AC 16 71 5
AD 37 71 5
AH 44 72 5
8
AE 40 56 5
AG 43 66 5
AM 95 64 4
AN 114 65 4
AP 146 58 5
IBS Before treatment IBS After treatment
4
BF 48 71 5
5
BD 45 73 5
BL 84 69 5 BF 69 72 5
BP 105 65 5 BN 134 70 5
BU 162 72 5 BO 129 72 5
11
BC 17 18 5
12
BB 29 38 4
BI 58 18 4 BE 90 28 4
BK 64 16 5 BG 72 16 4
BM 86 29 5 BK 68 21 5
BT 122 35 4 BM 106 55 5
CD Before treatment CD After treatment
6
CL 126 66 5
7
CL 163 71 5
CM 128 71 5 CM 133 72 5
CQ 142 70 5 CP 147 70 5
CP 140 72 4 CQ 149 70 5
13
CA 18 56 4
14
CD 73 43 4
CB 39 42 5 CG 88 18 4
CF 57 61 5 CJ 141 48 4
CG 82 9 4 CO 157 59 4
CH 93 5 5 CT 175 19 4
UC Before treatment UC After treatment
2
DG 38 71 5
3
DE 60 73 5
DL 116 72 5 DF 34 72 5
DM 139 72 5 DG 49 72 5
DN 160 60 5 DL 120 72 5
9
DB 14 4 4
10
DB 24 63 4
DE 30 37 4 DD 32 9 4
DF 31 54 5 DJ 108 62 4
DH 51 34 4 DK 111 58 4
DJ 98 58 5 DM 155 69 4
572
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Samples sequenced individually in the second 454 experiment
CD Before treatment CD After treatment
3 CQ 142 70 5 4 CQ 149 70 5
5 CD 47 71 4 6 CD 73 43 4
7 CG 82 9 4 8 CG 88 18 4
9 CH 93 5 5 10 CH 127 73 5
11 CM 128 71 5
12 CP 140 72 4
Healthy
13 AD 37 71 5
15 AE 40 56 5
16 AM 95 64 4
1: Equal quantities of DNA from 4 or 5 samples from each subgroup were sequenced. The first of the two pools574
was from samples that generated most FeS; the second from samples that generated slightly less FeS.575
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Table 3. Variation of SRB in 14 patient pools including 2 subgroups for each of the 7 patient groups
Healthy UC Before UC After IBS Before IBS After CD Before CD After
Intensity of FeS in culture High High High Low High Low High Low High Low High Low High Low
Barcode Pool No. 1 8 2 9 3 10 4 11 5 12 6 13 7 14
No. of sequence analysed 5,729 3,141 2,204 5,326 5,672 6,003 4,001 5,639 1,593 6,078 2,061 2,290 2,990 2,981
B. wadsworthia (100%
identical) 67.7 67.7 70.4 64.6 72.7 68.65 29.3 94.2 39.8 99.4 45.5 39.1 24.5 96.98
D. piger (> 99% identical) 27.25 24.5 24.2 7.1 22.8 4.5 44.7 0 36.1 0 32.2 40.3 52.2 0.1
New species A 0.95 0.1 1.3 17.35 0.7 11.8 24.7 1.9 16.7 0.65 1.4 14.5 0 2.92
New species B 0.6 3.9 4.1 10.55 3.8 1.4 0.2 0 1.3 0 6.5 2.6 0.4 0
New species C 2.75 3.2 0 0 0 0 0.2 0.1 0 0 0 0.1 0 0
D. vulgaris Hildenborough
(> 97% identical) 0 0 0 0 0 14.1 0 3.4 0 0 0 0 0.7 0
Desulfovibrio NY682 (>
98% identical) 0.55 0 0 0 0 0 0.0 0 0 0 0 2.6 9.9 0
D. desulfuricans F28-1 (>
98% identical) 0 0 0 0 0 0 0.6 0 6.0 0 0.0 0.6 0 0
New species D 0 0 0 0 0 0 0.0 0 0 0 15 0 12.1 0
Other 0.2 0.6 0 0.4 0 0.04 0.3 0.4 0.1 0 0 0.2 0 0
All SRB % 100 100 100 100 100 100 100 100 100 100 100 100 100 100
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Table 4. Diversity of SRB in individual patients
Patients with Crohn's disease Healthy controls
Patient No. CQ CD CG CH CM CP AD AE AM
Sample No. Before142
After
149
Before
47
After
73
Before
82
After
88
Before
93
After
127
Before
128
Before
140 37 40 95
Intensity of black FeS in culture High High High Low Low Low Low High High High High High High
No. of sequences analysed 2,999 2,985 1,238 2,976 3,001 2,987 2,993 2,975 3,000 2,999 3,000 2,998 3,010
B. wadsworthia (100% identical) 27.81 6.47 100 99.66 3.97 100 5.15 10.18 88.3 0 90.77 100 37.77
D. piger (> 99% identical) 70.92 92.13 0 0.34 0 0 94.29 88.84 0 37.91 0 0 62.19
New species A 0 0 0 0 91.2 0 0.13 0 0.9 1.63 3.2 0 0
New species B 0 0 0 0 0 0 0 0 10.8 0 0 0 0
New species C 0 0 0 0 0 0 0.17 0 0 0 5.73 0 0
D. vulgaris Hildenborough (> 97%
identical) 0 0 0 0 0 0 0 0 0 0 0 0 0
Desulfovibrio NY682 (> 98%
identical) 0 0 0 0 0 0 0 0 0 0 0 0 0
D. desulfuricans F28-1 (> 98%
identical) 0 0 0 0 4.83 0 0 0 0 0 0 0 0
New species D 1.27 1.41 0 0 0 0 0.27 0.34 0 60.42 0 0 0.33
Other 0 0 0 0 0 0 0 0.64 0 0.03 0.3 0 0
All SRB % 100 100 100 100 100 100 100 100 100 100 100 100 100
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Table 5. Clinical response of patients with Crohn’s disease to treatment as measured by the analysis of C-
reactive protein (CRP) and the Harvey & Bradshaw Index.
Patient
No.
Sample
No.
Before
Harvey &
Bradshaw
Index
CRP
(mg/l)
Sample
No.
After
Harvey &
Bradshaw
Index
CRP
(mg/l)
CA 18 9 96 27 7 7
CB 39 5 6 66 0 1
CC 46 7 5 56 3 2
CD 47 7 76 73 0 10
CE 53 6 n/a 61 3 n/a
CF 57 8 n/a 65 2 n/a
CG 82 15 33 88 2 1
CH 93 12 5 127 1 3
CI 117 6 5 123 2 2
CJ 121 4 10 141 0 12
CK 124 8 n/a 138 2 n/a
CL 126 5 n/a 163 5 40
CM 128 4 2 133 0 6
CN 131 8 97 136 2 14
CO 137 3 4 157 3 3
CP 140 11 2 147 3 n/a
CQ 142 8 27 149 2 5
CR 143 4 6 154 1 4
CS 164 9 56 172 2 n/a
CT 166 12 n/a 175 8 n/a
